Nfe2L2 Protein Nuclear Factor Erythroid 2 Related Factor 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Nuclear Factor Erythroid 2-Related Factor 2 |
|---|---|
| Gene | [NFE2L2](/genes/nfe2l2) |
| UniProt ID | Q16236 |
| PDB ID | 2Z35, 3ZGC |
| Molecular Weight | 66.3 kDa |
| Subcellular Localization | Cytoplasm (inactive), Nucleus (active) |
| Protein Family | bZIP transcription factor, CNC family |
NFE2L2 (commonly known as Nrf2) is a master transcriptional regulator of cellular antioxidant and cytoprotective responses. It is a basic leucine zipper (bZIP) transcription factor containing a highly conserved nef (NFE2) domain. Nrf2 regulates the expression of over 200 genes containing Antioxidant Response Elements (AREs) in their promoters, making it a critical hub for cellular defense against oxidative stress, electrophiles, and xenobiotics.
Nrf2 contains several functional domains:
Under basal conditions:
Upon activation:
Antioxidant enzymes: HO-1, NQO1, GCLM, GCLC, SOD1, CAT, GPx1
Detoxification: GSTs, UGTs, SULTs, MRP transporters
Proteostasis: p62, Hsp70, ubiquitin machinery
Metabolic enzymes: G6PD, IDH1, ME1
| Compound | Mechanism | Clinical Status |
|---|---|---|
| Dimethyl fumarate | Keap1 modification | Approved (MS), trials (AD) |
| Sulforaphane | Keap1 modification | Phase II (AD/PD) |
| Bardoxolone methyl | Keap1 modification | Phase II (AD) |
| Oltipraz | Various | Phase I/II |
The study of Nfe2L2 Protein Nuclear Factor Erythroid 2 Related Factor 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Yamamoto M, et al. Nat Rev Neurosci. 2018;19(8):477-489. PMID:29967479
[2] Baird L, et al. Annu Rev Pharmacol Toxicol. 2020;60:475-498. PMID:31680675
[3] Cuadrado A, et al. Nat Rev Drug Discov. 2019;18(4):295-317. PMID:30610274
[4] Robledinos-Añover N, et al. Free Radic Biol Med. 2022;188:92-107. PMID:35644462
[5] Lastres-Becker I, et al. Neuropharmacology. 2022;210:109028. PMID:35259589